Semaglutide vs Tirzepatide
Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist. Head-to-head metabolic data show tirzepatide producing larger average weight loss and larger A1C reductions, while semaglutide carries the longer cardiovascular outcome track record in defined populations. The right molecule is a provider-reviewed match against biomarkers, tolerance, history, and access.
Choose semaglutide when the longer cardiovascular outcome track record is the priority, when tirzepatide is not accessible, or when prior tolerance favors GLP-1 mono-agonism.
Choose tirzepatide when the priority endpoint is maximum weight loss or A1C reduction at tolerated dose, and access and candidacy support it.
Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
Is tirzepatide always better than semaglutide?
No. Tirzepatide produces larger average effects in head-to-head data, but candidacy, tolerance, cardiovascular history, access, and prior GLP-1 exposure all shape the match. It is a provider-reviewed decision.
Do both cause muscle loss?
All meaningful weight loss includes a lean-mass fraction. The fraction is largely preventable with a protein floor (1.2–1.6 g/kg of reference body weight), resistance training 2–3x/week, and titration matched to the patient's intake capacity.
Can I switch between molecules?
Switching is provider-reviewed and depends on tolerance, response, candidacy, and access. It is not a self-directed change.
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment